Tagged with M&A

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…

Japan “This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said Christophe Weber, Takeda’s CEO, after the USD 62 billion acquisition of international biotech Shire was completed in 2019. Two years later, the Japanese giant appears to finally be on…

China Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world, his talent strategy, and the use of AI within the sector.   BioDuro has very strong capabilities on the discovery…

Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a Switzerland-based specialty pharma player focused on the digestive system, shares his M&A principles and insights, their exciting recent acquisition of DIFICLIR™ from Astellas, and the company’s recognition as a Great Place to Work® (GPTW) in Switzerland.   For…

Global In November 2020, after months of delay caused by COVID-19 disruptions and a US antitrust roadblock, Mylan and Pfizer’s Upjohn generics unit finally closed a USD 12 billion merger. The combined new company, ‘Viatris’, boasts a global workforce of over 45,000, 50 manufacturing sites, and a presence in 165 countries,…

M&A In the wake of Sanofi’s USD 3.7 billion tie-up for US biotech Principia, J&J has moved to bolster its autoimmune portfolio with the acquisition of Momenta Pharmaceuticals for USD 6.5 billion, a further signal of Big Pharma’s prioritisation of rare disease treatments.   The all-cash deal sees J&J’s pharmaceutical division…

Sanofi Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline of BTK inhibitors for autoimmune disorders.   The deal, whereby Sanofi is set to pay USD 100 a share to…

Korea Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another big-money deal for Takeda.   Since Takeda’s earthshattering announcement of its intended USD 62 billion acquisition of Shire – the…

Italy Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of Stemline Therapeutics.   The deal, said to be worth USD 677 million, was announced on 4 May 2020 and completed on 10 June. The acquisition of Stemline,…

Romania With the 2019 acquisition of Celgene – one of the largest pharma acquisition in history – two of the sector’s most innovative oncology companies have joined forces to lead the charge against cancer. The combined entity is expected to rise in the global biopharma rankings, complete with a fresh new…

Romania Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a state-of-art stem cell therapy. She highlights the organisational changes in the last year, and how they have been inducive to double-digit growth for Takeda. Additionally, she reveals…

Czech Republic Kieran Leahy, general manager of Takeda in the Czech Republic and Slovakia, recounts how he has led the transformation of Takeda into a specialty care organization at the local level, and his priorities to successfully integrate Shire along this journey. Leahy also breaks down the market access challenges in the…